Wednesday, 22 January 2020

AMRI acquires Cedarburg at $41mn

08 April 2014 | News | By BioSpectrum Bureau

Singapore: AMRI has completed the acquisition of Cedarburg Pharmaceuticals, a contract developer and manufacturer of technically complex active pharmaceutical ingredients (API's) for both generic and branded customers.

Total consideration paid was USD41 million, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition is expected to add between USD13 and USD14 million to AMRI's revenue in 2014.

AMRI anticipates full year run-rate synergies of approximately USD1.5 million of EBITDA within 12 months of closing.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls